Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in lewy body diseases

Journal of Neuroscience Research

Volumn 87, Issue 4, 2009, Pages 1002-1013

  Gómez, Anna ^a   Ferrer, Isidre ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Aldolase A; Dementia with Lewy bodies; Enolase 1; Glyceraldehyde dehydrogenase; Incidental Lewy body disease; Lewy body disease; Oxidative damage; Parkinson disease

Indexed keywords

4 HYDROXYNONENAL; ENOLASE; ENOLASE 1; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE A; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; UNCLASSIFIED DRUG; 4-HYDROXY-2-NONENAL; ALDEHYDE; DNA BINDING PROTEIN; ENO1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BRAIN DYSFUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DENSITOMETRY; DIFFUSE LEWY BODY DISEASE; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME MODIFICATION; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; MALE; MASS SPECTROMETRY; METABOLIC ENCEPHALOPATHY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; FRONTAL LOBE; GLYCOLYSIS; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY;

AGED; AGED, 80 AND OVER; ALDEHYDES; BLOTTING, WESTERN; DENSITOMETRY; DNA-BINDING PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENERGY METABOLISM; FEMALE; FRONTAL LOBE; FRUCTOSE-BISPHOSPHATE ALDOLASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GLYCOLYSIS; HUMANS; LEWY BODY DISEASE; MALE; MASS SPECTROMETRY; MIDDLE AGED; OXIDATION-REDUCTION; PARKINSON DISEASE; PHOSPHOPYRUVATE HYDRATASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 63849244747     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21904     Document Type: Article

References (59)

1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. 1997. A generalized increase in protein carbonyls in the brain in Parkinson's disease but not in incidental Lewy body disease. J Neurochem 69:1326-1329.
2. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, Butterfield DA. 2005a. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 1044:206-215.
3. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA. 2005b. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132:313-324.
4. Braak H, Braak E. 1999. Temporal sequence of Alzheimer's disease-related pathology. In: Peters A, Morrison JH, editors. Cerebral cortex, vol 14, Neurodegenerative and related changes in structure and function of cerebral cortex. New York: Kluwer Academic/Plenum Publishers. p 475-512.
5. Braak H, Del Tredici K, Rüb U, de Vos RA, Cansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
6. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tedici K. 2004. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-134.
7. Braak H, Rüb U, Jansen Steur EN, Del Treedici K, de Vos RA. 2005. Cognitive status correlated with neuropathologic state in Parkinson disease. Neurology 64:1404-1410.
8. Buono P, D'Armiento FP, Terzi G, Alfieri A, Salvatore F. 2001. Differential distribution of aldolase A and C in the human central nervous system. J Neurocytol 30:957-965.
9. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, Martins RN. 2006a. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis 10:391-397.
10. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR. 2006b. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22:223-232.
11. Caballol N, Marti MJ, Tolosa E. 2007. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 22:S358-S366.
12. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. 2002. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain: part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82:1524-1532.
13. Castellani R, Smith MA, Richey PL, Perry G. 1996. Glycoxidation and oxidative stress in Parkinson's disease and diffuse Lewy body disease. Brain Res 737:195-200.
14. Ceballos I, Lafon M, Javoy-Agid F, Hirsch E, Nicole A, Sinet PM, Agid Y. 1990. Superoxide dismutase and Parkinson's disease. Lancet 335: 1035-1036.
15. Dalfó E, Ferrer I. 2008. Early a-synuclein lipoxidation in neocortex in Lewy body diseases. Neurobiol Aging 29:408-417.
16. Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I. 2005. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816-830.
17. Dexter DT, Carter C, Agid F. 1986. Lipid peroxidation as a cause of nigral death in Parkinson's disease. Lancet 2:639-640.
18. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
19. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AH. 1994. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35:38-44.
20. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S, Budka H, Carmona M, Giaccone G, Krebs B, Limido L, Parchi P, Puig B, Strammiello R, Strobel T, Kretzschmar H. 2007. Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol 66:35-46.
21. Ferrer I, Martinez A, Boluda S, Parchi P, Barrachina M. 2008. Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 9: 181-194.
22. Floor E, Wetzel MG. 1998. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70:268-275.
23. Forno LS. 1996. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272.
24. Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH. 2000. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol 166: 324-333.
25. Goedert M. 2001. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492-501.
26. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. 2007. Changes in network activity with the progression of Parkinson's disease. Brain 130:1834-1846.
27. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. 2008. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70:1470-1477.
28. Ince PG, McKeith I. 2003. Dementia with Lewy bodies. In: Dickson D, editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press. p 188-199.
29. Jellinger K, Mizuno Y. 2003. Parkinson's disease. In: Dickson D, editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press. p 159-187.
30. Jenner P. 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13:24-34.
31. Jenner P. 2003. Oxidative stress in Parkinson's disease. Ann Neurol 53(Suppl 3):S26-S38.
32. Karagulle Kendi AT, Lehericy S, Luciana M, Ugurbil K, Tuite P. 2008. Altered diffusion in the frontal lobe in Parkinson's disease. Am J Neuroradiol 29:501-505.
33. Keller A, Berod A, Dussaillant M, Lamande N, Gros F, Lucas M. 1994. Coexpression of alpha and gamma enolase genes in neurons of adult rat brain. J Neurosci Res 38:493-504.
34. Levin BE, Katzen HL. 2005. Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. Adv Neurol 96:84-94.
35. Markesberry WR, Montine TJ, Lovell MA. 2001. Oxidative alterations in neurodegenerative diseases. In: Mattson MP, editor. Pathogenesis of neurodegenerative diseases. Totowa, NJ: Humana Press. p 21-51.
36. Martínez A, Dalfo E, Muntane G, Ferrer I. 2008. Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy. J Neural Transm 115:59-66.
37. Marttila RJ, Lorentz H, Rinne UK. 1988. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86:321-331.
38. Mazzola JL, Sirover MA. 2005. Aging of human glyceraldehyde-3-phosphate dehydrogenase is dependent on its subcellular localization. Biochim Biophys Acta 1722:168-174.
39. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien J, Playfer J, Reid W,International Psycogeriatric Association Expert Meeting on DLB. 2004. Dementia with Lewy bodies. Lancet Neurol 3:19-28.
40. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boewe B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Kocyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Landinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M,Consortium on DLB. 2006. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863-1872.
41. McNamara P, Durso R, Harris E. 2007. Machiavelism and frontal dysfunction: evidence from Parkinson's disease. Cogn Neuropsychiatr 12: 285-300.
42. Olah J, Tokesi N, Vincze O, Horvath I, Lehotzky A, Erdei A, Szajli E, Medzihradszky KF, Orosz F, Kovacs GG, Ovadi J. 2006. Interaction of TPPP/ p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. FEBS Lett 580:5807-5814.
43. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144.
44. Opii WO, Nukala VN, Sultana R, Pandya JD, Day KM, Merchant ML, Klein JB, Sullivan PG, Butterfield DA. 2007. Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury. J Neurotrauma 24:772-789.
45. Perry TL, Godin DV, Hansen S. 1982. Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci Lett 33:305-310.
46. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. 2005. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice - a model of familial Parkinson's disease. Neurobiol Dis 18:492-498.
47. Poon HF, Shepherd HM, Reed TT, Calabrese V, Stella AM, Pennisi G, Cai J, Pierce WM, Klein JB, Butterfield DA. 2006. Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. Neurobiol Aging 27:1020-1034.
48. Saggu H, Cooksey J, Dexter D, Welles FR, Lees A, Jenner P, Marsden CD. 1989. A selective increase in particulate superoxide dismutase activity in Parkinson's substantia nigra. J Neurochem 53:692-697.
49. Santpere G, Puig B, Ferrer I. 2006. Low molecular weight species of tau in Alzheimer's disease are dependent on tau phosphorylation sites but not on delayed post-mortem delay in tissue processing. Neurosci Lett 399:106-110.
50. Shelley ML. 1998. 4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med 25:169-174.
51. Shults CW. 2006. Lewy bodies. Proc Nat Acad Sci USA 103:1661-1668.
52. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. 1994. Alterations in glutathione levels in Parkinson's disease patients. Genomics 17:171-184.
53. Silberman CD, Laks J, Capitäo CF, Rodrigues CS, Moreira I, Vasconcellos LF, Engelhardt E. 2007. Frontal functions in depressed and nondepressed Parkinson's disease patients: impact of severity stages. Psychiatry Res 149:285-289.
54. Sirover MA. 2005. New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. J Cell Biochem 95:45-52.
55. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA. 2006. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27:1564-1576.
56. Tessa C, Gianelli M, Della Nave R, Lucetti C, Berti C, Ginestroni A, Bonuccelli U, Mascalchi M. 2008. A whole-brain analysis in de novo Parkinson disease. Am J Neuroradiol 29:674-680.
57. Tsuchiya K, Tajima H, Kuwae T, Takeshima T, Nakano T, Tanaka M, Sunaga K, Fukuhara Y, Nakashima K, Ohama E, Mochizuki H, Mizuno Y, Katsube N, Ishitani R. 2005. Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions. Eur J Neurosci 21:317-326.
58. Wolters ECh, Braak H. 2006. Parkinson's disease: premotor clinico-pathological correlations. J Neural Transm Suppl 70:309-319.
59. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. 1996. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93:696-701.